<DOC>
	<DOCNO>NCT01750086</DOCNO>
	<brief_summary>The aim study assess relative antiresorptive property 2 osteoporosis medication combine teriparatide .</brief_summary>
	<brief_title>Acute Effect Teriparatide With Bisphosphonate Denosumab Bone Resorption</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Bone Resorption</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Must satisfy A B C : A . Women age 45+ B. Postmenopausal C. Osteoporotic high risk fracture History significant hepatic , renal , cardiovascular , malignant disease , condition impair immune system Current alcohol substance abuse Major psychiatric disorder Abnormal calcium level , elevate PTH , vitamin D deficiency , anemia Known congenital acquire bone disease osteoporosis Current use past use past 12 month oral bisphosphonates Current use use past 3 month estrogen , selective estrogen receptor modulators , calcitonin Use oral parenteral glucocorticoid 14 day past 6 month Any current previous use strontium intravenous bisphosphonates Sensitivity cellderived drug product teriparatide Extensive dental work involve dental extraction dental implant within past 2 month upcoming 2 month Inability sit upright 30 minute Esophageal abnormality</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>denosumab</keyword>
	<keyword>teriparatide</keyword>
	<keyword>alendronate</keyword>
	<keyword>Forteo®</keyword>
	<keyword>Prolia®</keyword>
</DOC>